Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With a-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan
alogliptin
SYR-322/CCT-003
NCT01263483
Diabetes Mellitus, Type 2
Phase 3
 
Select supporting documents are N/A in English and as such are N/A for sharing at this time.
October 2014

Powered by ideaPoint, Inc.